Muehleman D, Gruner B, Hogan V, Fanning P, Garrett C, Meyer J
Emerg Infect Dis. 2024; 30(14):53-61.
PMID: 39530855
PMC: 11559565.
DOI: 10.3201/eid3014.240231.
Tsagkli P, Geropeppa M, Papadatou I, Spoulou V
Vaccines (Basel). 2024; 12(9).
PMID: 39340081
PMC: 11436074.
DOI: 10.3390/vaccines12091051.
Yamamoto S, Matsuda K, Maeda K, Mizoue T, Horii K, Okudera K
Open Forum Infect Dis. 2024; 11(9):ofae519.
PMID: 39319092
PMC: 11420683.
DOI: 10.1093/ofid/ofae519.
Yan S, Luo Y, Zhan N, Xu H, Yao Y, Liu X
Microbiol Spectr. 2024; 12(10):e0069224.
PMID: 39145626
PMC: 11448059.
DOI: 10.1128/spectrum.00692-24.
Nowakowska A, Lee S, Kim M, Chun J, Kim S, Kim B
Front Immunol. 2024; 15:1359209.
PMID: 39040104
PMC: 11260787.
DOI: 10.3389/fimmu.2024.1359209.
Correlates of protection against symptomatic SARS-CoV-2 in vaccinated children.
Zhong Y, Kang A, Tay C, Li H, Elyana N, Tan C
Nat Med. 2024; 30(5):1373-1383.
PMID: 38689059
PMC: 11164684.
DOI: 10.1038/s41591-024-02962-3.
Modelling COVID-19 Vaccination in the UK: Impact of the Autumn 2022 and Spring 2023 Booster Campaigns.
Mendes D, Machira Krishnan S, OBrien E, Padgett T, Harrison C, Strain W
Infect Dis Ther. 2024; 13(5):1127-1146.
PMID: 38662331
PMC: 11098993.
DOI: 10.1007/s40121-024-00965-8.
Cellular Immunity of SARS-CoV-2 in the Borriana COVID-19 Cohort: A Nested Case-Control Study.
Domenech-Montoliu S, Puig-Barbera J, Pac-Sa M, Orrico-Sanchez A, Gomez-Lanas L, Sala-Trull D
Epidemiologia (Basel). 2024; 5(2):167-186.
PMID: 38651389
PMC: 11036210.
DOI: 10.3390/epidemiologia5020012.
Humoral and cell-mediated immune responses in HIV-vertically infected young patients after three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine.
Vanetti C, Stracuzzi M, Crivellaro E, Ciciliano F, Garziano M, Fenizia C
Front Immunol. 2024; 14:1301766.
PMID: 38250079
PMC: 10797701.
DOI: 10.3389/fimmu.2023.1301766.
SARS-CoV-2 Humoral Immunity Persists Following Rituximab Therapy.
Lu L, Chan C, Lim Y, Than M, Teo S, Lau P
Vaccines (Basel). 2023; 11(12).
PMID: 38140267
PMC: 10748262.
DOI: 10.3390/vaccines11121864.
Persistent humoral immune response in youth throughout the COVID-19 pandemic: prospective school-based cohort study.
Raineri A, Radtke T, Rueegg S, Haile S, Menges D, Ballouz T
Nat Commun. 2023; 14(1):7764.
PMID: 38012137
PMC: 10682435.
DOI: 10.1038/s41467-023-43330-y.
Real-World Study: Hybrid Immunity against SARS-CoV-2 Influences the Antibody Levels and Persistency Lasting More than One Year.
Kanokudom S, Chansaenroj J, Assawakosri S, Suntronwong N, Yorsaeng R, Wongsrisang L
Vaccines (Basel). 2023; 11(11).
PMID: 38006025
PMC: 10674428.
DOI: 10.3390/vaccines11111693.
Monovalent Omicron COVID-19 vaccine triggers superior neutralizing antibody responses against Omicron subvariants than Delta and Omicron bivalent vaccine.
Li W, Zhao T, Tao B, Zhao L, Xiao H, Ding X
Hum Vaccin Immunother. 2023; 19(2):2264589.
PMID: 37846840
PMC: 10583637.
DOI: 10.1080/21645515.2023.2264589.
Risk factors and titers of COVID-19 infection in a longitudinal statewide seroepidemiology cohort.
Rogawski McQuade E, Becker L, Stroup S, Khan F, Shah B, Brush J
BMC Infect Dis. 2023; 23(1):676.
PMID: 37821853
PMC: 10565985.
DOI: 10.1186/s12879-023-08670-6.
SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-December 2022.
Kagucia E, Ziraba A, Nyagwange J, Kutima B, Kimani M, Akech D
Influenza Other Respir Viruses. 2023; 17(9):e13173.
PMID: 37752065
PMC: 10522478.
DOI: 10.1111/irv.13173.
The evolution of SARS-CoV-2 seroprevalence in Canada: a time-series study, 2020-2023.
Murphy T, Swail H, Jain J, Anderson M, Awadalla P, Behl L
CMAJ. 2023; 195(31):E1030-E1037.
PMID: 37580072
PMC: 10426348.
DOI: 10.1503/cmaj.230249.
Development of hybrid immunity during a period of high incidence of Omicron infections.
Frei A, Kaufmann M, Amati R, Butty Dettwiler A, von Wyl V, Annoni A
Int J Epidemiol. 2023; 52(6):1696-1707.
PMID: 37407273
PMC: 10749742.
DOI: 10.1093/ije/dyad098.
Changing Severity and Epidemiology of Adults Hospitalized With Coronavirus Disease 2019 (COVID-19) in the United States After Introduction of COVID-19 Vaccines, March 2021-August 2022.
Kojima N, Adams K, Self W, Gaglani M, McNeal T, Ghamande S
Clin Infect Dis. 2023; 77(4):547-557.
PMID: 37255285
PMC: 10526883.
DOI: 10.1093/cid/ciad276.
Impaired humoral immunity to BQ.1.1 in convalescent and vaccinated patients.
Dewald F, Pirkl M, Paluschinski M, Kuhn J, Elsner C, Schulte B
Nat Commun. 2023; 14(1):2835.
PMID: 37208323
PMC: 10199003.
DOI: 10.1038/s41467-023-38127-y.
Frontline Worker Safety in the Age of COVID-19: A Global Perspective.
Kavanagh K, Maiwald M, Pontus C, Cimiotti J, Palmieri P, Cormier L
J Patient Saf. 2023; 19(5):293-299.
PMID: 37162150
PMC: 10373843.
DOI: 10.1097/PTS.0000000000001132.
